학술논문
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Document Type
Artikel
Author
Source
Multiple sclerosis (Houndmills, Basingstoke, England). 28(5):842-846
Subject
Language
English
English
English
ISSN
1477-0970